Abstract
Background
Rapid decreases in activated CD4+ and CD8+ (HLA-DR + and CD38+ co-expressed) T-lymphocytes have been described within 1–2 weeks of initiating direct-acting antiviral (DAA) therapy among chronic Hepatitis C (CHC) patients. However, it is not known whether these changes are maintained past sustained virologic response (SVR), particularly in those who are HIV/HCV-coinfected.
Methods
We investigated the changes in immune parameters of T-lymphocytes from pre-DAA therapy to post-SVR among HIV negative and HIV positive patients with CHC. Repeated measurements of activated CD4+ and CD8+ T cells were analyzed by flow cytometry at pre-DAA therapy, DAA therapy, end of treatment, SVR, and post-SVR. A general linear model for repeated measurements was used to estimate the mean outcome at each timepoint and change between timepoints.
Results
HCV-monoinfected (n = 161) and HIV/HCV-coinfected (n = 59) patients who achieved SVR with DAA therapy were predominately middle aged, male, black, and non-cirrhotic. At pre-DAA therapy, HCV-monoinfected patients had significantly higher CD4+ T cells and CD4+:CD8+ T-cell ratio, while significantly lower CD8+ and activated CD4+ and CD8+ T cells compared to HIV/HCV-coinfected patients (p < 0.0001). HCV-monoinfected and HIV/HCV-coinfected patients had a significant mean decrease from pre-DAA therapy to post-SVR year 1 for activated CD4+ (HCV-monoinfected: 4.8–3.9%, p < 0.0001; HIV/HCV-coinfected: 6.6–4.5%, p < 0.0001) and activated CD8+ T cells (HCV-monoinfected V: 13.8–11.8%, p = 0.0002; HIV/HCV-coinfected: 18.0–12.4%, p < 0.0001).
Conclusion
This longitudinal study showed CHC patients treated with DAA therapy had continued decrease of T-lymphocytes from start of DAA therapy to after achievement of SVR suggesting improvement as HCV clearance normalizes activated T-cell phenotype.
Similar content being viewed by others
References
Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010;85:303–315
Centers for Disease Control and Prevention. Viral Hepatitis Surveillance United States, 2014 [Internet]. 2014. http://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of Hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562–569
Hernandez MD, Sherman KE. HIV/HCV coinfection natural history and disease progression, a review of the most recent literature. Curr Opin HIV AIDS 2011;6:478–482
Rotman Y, Liang TJ. Coinfection with Hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009;83:7366–7374
Zaegel-Faucher O, Bregigeon S, Cano CE, Obry-Roguet V, Nicolino-Brunet C, Tamalet C, et al. Impact of Hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy. AIDS 2015;29:1505–1510
Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with Hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009;83:11407–11411
Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol 2013;3:461–467
Harcourt G, Gomperts E, Donfield S, Klenerman P. Diminished frequency of hepatitis C virus specific interferon γ secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 2006;55:1484–1487
Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Zur Wiesch JS, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood.2005;105:1170–1178
Feuth T, Arends JE, Fransen JH, Nanlohy NM, van Erpecum KJ, Siersema PD, et al. Complementary role of HCV and HIV in T-Cell activation and exhaustion in HIV/HCV coinfection. PLoS ONE [Internet] 2013 [cited 2015 Oct 15];8. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598709/
Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A. CD8+ T cell activation in women coinfected with human immunodeficiency virus type 1 and Hepatitis C virus. J Infect Dis 2008;197:1402–1407
Sandberg JK, Falconer K, Gonzalez VD. Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients. Virulence 2010;1:177–179
Hodowanec AC, Brady KE, Gao W, Kincaid SL, Plants J, Bahk M, et al. Characterization of CD4+ T-cell immune activation and interleukin 10 levels among HIV, Hepatitis C virus, and HIV/HCV-coinfected patients. JAIDS J Acquir Immune Defic Syndr 2013;64:232–240
Najafi Fard S, Schietroma I, Corano Scheri G, Giustini N, Serafino S, Cavallari EN, et al. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clin Res Hepatol Gastroenterol [Internet] 2017 [cited 2018 Jan 23]. http://www.sciencedirect.com/science/article/pii/S2210740117302620
Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631–640
Meissner EG, Kohli A, Higgins J, Lee Y-J, Prokunina O, Wu D, et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun 2017;1:586–594
Barrett L, Shivasabesan G, Wang C, Osinusi A, Kohli A, Meissner EG, et al. 1 altered HCV specific T cell immunity very early in interferon free HCV DAA therapy. J Hepatol 2013;58(Supplement 1):S1
Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014;61:538–543
Osinusi A, Meissner EG, Lee Y-J, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for Hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804–811
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015;385:1107–1113
Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis 2016;62:280–288
Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, et al. Re-treatment of chronic Hepatitis C virus genotype 1 infection after relapse: an open-label pilot Study. Ann Intern Med 2014;161:634–638
Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-Hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis 2016;62:440–447
Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with Hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial anti-HCV regimens in noncirrhotic patients with genotype 1 infection. Ann Intern Med 2015;163:899–907
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232–1239
Rosenthal ES, Howard L, Purdy J, McLaughlin M, Kattakuzhy S, Kohli A, et al. Virologic response following asunaprevir/daclatasvir with or without beclabuvir for treatment of HCV genotype 1 in patients co-infected with HIV. J Hepatol 2016;64:S760–S761
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
B. Emmanuel, S.S. El-Kamary, L.S. Magder, K.A. Stafford, M.E. Charurat, B. Poonia, C. Chairez, M. McLaughlin, C. Hadigan, H. Masur, and S. Kottilil have no conflict of interest.
Ethical standard
The primary study was approved by the NIAID IRB and conducted in compliance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and regulatory requirements.
Informed consent
All patients provided written informed consent and all protocols were approved by the NIH/NIAID Institutional Review Board.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Emmanuel, B., El-Kamary, S.S., Magder, L.S. et al. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients. Hepatol Int 13, 270–276 (2019). https://doi.org/10.1007/s12072-019-09941-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-019-09941-8